


RESEARCH ARTICLE

Cutaneous leishmaniasis and co-morbid major depressive disorder: A systematic review with burden estimates

Freddie Bailey^{1,2}, Karina Mondragon-Shem³, Lee Rafuse Haines^{1,3}, Amina Olabi¹, Ahmed Alorfi⁴, José Antonio Ruiz-Postigo⁵, Jorge Alvar⁶, Peter Hotez⁷, Emily R. Adams¹, Iván D. Vélez⁸, Waleed Al-Salem⁴, Julian Eaton^{9,10}, Álvaro Acosta-Serrano^{1,3}, David H. Molyneux^{1*}

1 Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, United Kingdom, **2** Milton Keynes University Hospital, Eaglestone, Milton Keynes, United Kingdom, **3** Department of Vector Biology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, United Kingdom, **4** National Centre for Tropical Diseases, National Health Laboratory, Ministry of Health—Kingdom of Saudi Arabia, Riyadh, Kingdom of Saudi Arabia, **5** World Health Organization, Geneva, Switzerland, **6** Drugs for Neglected Disease Initiative, Geneva, Switzerland, **7** National School of Tropical Medicine, Baylor College of Medicine, Texas, United States of America, **8** Programa de Estudio y Control de Enfermedades Tropicales PECET, Universidad de Antioquia, Medellín, Colombia, **9** CBM International, Dry Drayton Road, Oakington, Cambridge, United Kingdom, **10** London School of Hygiene and Tropical Medicine, Keppel Street, London, United Kingdom

* david.molyneux@lstm.ac.uk



OPEN ACCESS

Citation: Bailey F, Mondragon-Shem K, Haines LR, Olabi A, Alorfi A, Ruiz-Postigo JA, et al. (2019) Cutaneous leishmaniasis and co-morbid major depressive disorder: A systematic review with burden estimates. *PLoS Negl Trop Dis* 13(2): e0007092. <https://doi.org/10.1371/journal.pntd.0007092>

Editor: Marleen Boelaert, Institute of Tropical Medicine, BELGIUM

Received: August 23, 2018

Accepted: December 18, 2018

Published: February 25, 2019

Copyright: © 2019 Bailey et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript and its Supporting Information files.

Funding: We acknowledge support from Sanofi and the SHEFA Fund. WAS is supported by the Saudi Ministry of Health. KMS is supported by a PhD studentship from the Colombian Department for Science, Technology and Innovation (Colciencias). The funders had no role in study

Abstract

Background

Major depressive disorder (MDD) associated with chronic neglected tropical diseases (NTDs) has been identified as a significant and overlooked contributor to overall disease burden. Cutaneous leishmaniasis (CL) is one of the most prevalent and stigmatising NTDs, with an incidence of around 1 million new cases of active CL infection annually. However, the characteristic residual scarring (inactive CL) following almost all cases of active CL has only recently been recognised as part of the CL disease spectrum due to its lasting psychosocial impact.

Methods and findings

We performed a multi-language systematic review of the psychosocial impact of active and inactive CL. We estimated inactive CL (iCL) prevalence for the first time using reported WHO active CL (aCL) incidence data that were adjusted for life expectancy and underreporting. We then quantified the disability (YLD) burden of co-morbid MDD in CL using MDD disability weights at three severity levels. Overall, we identified 29 studies of CL psychological impact from 5 WHO regions, representing 11 of the 50 highest burden countries for CL. We conservatively calculated the disability burden of co-morbid MDD in CL to be 1.9 million YLDs, which equaled the overall (DALY) disease burden (assuming no excess mortality in depressed CL patients). Thus, upon inclusion of co-morbid MDD alone in both active and

design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

inactive CL, the DALY burden was seven times higher than the latest 2016 Global Burden of Disease study estimates, which notably omitted both psychological impact and inactive CL.

Conclusions

Failure to include co-morbid MDD and the lasting sequelae of chronic NTDs, as exemplified by CL, leads to large underestimates of overall disease burden.

Author summary

Cutaneous leishmaniasis is a highly prevalent vector-borne disease affecting large parts of Latin America and the Middle East, as well as parts of Northern Africa. There are several types of Cutaneous leishmaniasis, almost all of which have an active phase characterized by a disfiguring lesion (typically on exposed parts of the body), which then becomes a permanent scar (the inactive phase). We recently published an article highlighting the impact of the inactive scarring phase of CL on affected individuals, which is associated with high levels of stigma. Nevertheless, this aspect of the disease is not considered in its own right when calculating the overall disease burden by the Global Burden of Disease (GBD) Studies. In this article we estimate the prevalence of depression (major depressive disorder) in cutaneous leishmaniasis, in both the active and inactive forms. We then show the contribution of inactive CL to the overall disease burden estimates when included, which is due to the large psychological impact it has on those affected by it. We also highlight the importance of further similar efforts for other NTDs which have a chronic course, and which are also not sufficiently included in disease burden calculations at present.

Introduction

Cutaneous leishmaniasis

Cutaneous leishmaniasis (CL) is the most prevalent form of leishmaniasis and 1 of 22 highly prevalent neglected tropical diseases (NTD) [1]. Current disease classifications differentiate aspects of the active (nodular, ulcerative or plaque) CL lesion in terms of its transmission route (“zoonotic” vs “anthroponotic”), geographical location (“New World” vs “Old World”), and extent of its dermatological manifestations (“diffuse” vs “localised”) [2]. However, none capture the characteristic stigmatisation and psychological sequelae of life-long residual CL scarring that accompanies active infection in almost all cases. As such, we recently expanded the spectrum of CL disease by introducing new terminology—active (aCL) and inactive (iCL) scarring cutaneous leishmaniasis—to describe the dermatological changes of CL in relation to its disease activity [3]. Such a classification is also inclusive of long-term sequelae such as mucocutaneous leishmaniasis (MCL), which develops in a minority of CL cases (~4%) [4] mainly in the Americas and East African regions and which may represent a reactive form of CL [5].

The stigmatisation resulting from visible active and inactive CL lesions can be traced back centuries and was probably a major driver in establishing the ancient practice of leishmanisation [6]. Nevertheless, this defining psychosocial aspect of cutaneous leishmaniasis has been almost completely overlooked by successive disease burden studies [7–10]. Furthermore, the prevalence of inactive CL has not previously been estimated and as such is not presently incorporated into burden estimates. This unfortunately underlines a habitual lack of consideration

for the chronic sequelae of NTDs. Regrettably, as CL is not a life-limiting infection, policy-makers often neglect CL as a priority disease [11–13] despite its importance to endemic communities and its links to poverty [14]. This oversight is particularly problematic given the increasing CL incidence in highly endemic conflict zones of Afghanistan, Iraq, the Syrian Arab Republic, and Yemen, creating a major public health problem [15,16].

Major depressive disorder (“depression”)

Major Depressive Disorder (MDD) is the most prevalent form of mental disorder, affecting 4.4% of world’s population [17]. The diagnosis of MDD is symptom-based and follows the Disease Statistical Manual (DSM). MDD is one of two depressive disorders that account for the fifth largest cause of disability (years of life lived with disability; YLD) in the latest 2016 Global Burden of Disease (GBD) Study [18]. There is also a growing recognition by the global mental health community of the importance of adopting a more inclusive approach to mental health and disease, from wellness to subclinical distress to clinical “disorder”, known as the staged model of depression [19].

The psychological impact of the NTDs is an area that has only recently been emphasised in the NTD community [20]. For example, mental ill health was not included in recent calculations of disability-adjusted life years (DALYs) averted by NTD programmes, suggesting that the psychological impact of these conditions is not a primary outcome of such programmes [21]. It is therefore unsurprising that previous global burden of depression studies appear to exclude NTDs from their prevalence and burden estimates [17,22,23]. This omission is highly significant for two reasons: Many of NTDs are uniquely stigmatising [20], and collectively, WHO estimates that NTDs affect over 1 billion (or 1 in 6) people worldwide [1].

In summary, CL is often ignored at the policy level due to its lack of mortality, and is therefore a prime example of a stigmatising, prevalent NTD whose associated mental illness is disregarded. The aims of the present study are two-fold: 1) To conduct a systematic review of the psychological impact of cutaneous leishmaniasis; 2) To quantify the burden of co-morbid major depressive disorder in this highly prevalent and stigmatising condition for the first time.

Methods

Our study reflects the current approach to disease burden estimates, which are based upon MDD as classified by the DSM [22]. We have also adopted the staged model of depression to use additional evidence from psychological and quality of life studies. These latter studies were used to calculate stages of subclinical distress associated with CL and to quantify its overall psychosocial impact.

There are four steps to calculating the burden of co-morbid depression (in DALYs) due to CL. Firstly, we conducted a systematic review of the psychosocial impact of all forms of CL (including MCL). To quantify the overall impact of iCL as part of the burden of CL, we also had to generate estimates of iCL prevalence for the first time. Following these first two steps, we then estimated the prevalence of MDD co-morbidity and its severity in aCL and iCL patients. We did not calculate the burden of co-morbid MCL as the associated mortality rate is not known and therefore prevalence estimates could not be reliably calculated. Finally, we multiplied the prevalence of aCL and iCL with co-morbid MDD by the disability weight (DW) for MDD at three severity levels (mild, moderate, and severe) following the methodology of Ton *et al* (2015) [24] (see Fig 1).

The search strategy queried four Ovid databases—Medline [25], EMBASE [26], Global Health [27], and PSYCInfo [28]—as well as LILACS [29], using English, French, Spanish, and Portuguese search terms on 4th December 2017. Additional searches through Google Scholar

$$\text{DALY}_{(\text{MDD}\sim\text{CL})} = q * \text{DALY}_{(\text{CL})}$$

Or

$$\text{DALY}_{(\text{MDD}\sim\text{CL})} = \text{YLL}_{(\text{MDD}\sim\text{CL})} + \text{YLD}_{(\text{MDD}\sim\text{CL})}$$

YLL = Years of Life Lost due to a condition;
YLD = Years of Life Lived with Disability from a condition

$$\text{YLL}_{(\text{MDD}\sim\text{CL})} = \text{N}_{(\text{MDD}\sim\text{CL})} \times \text{L}_{(\text{MDD}\sim\text{CL})} \qquad \text{YLD}_{(\text{MDD}\sim\text{CL})} = \text{P}_{(\text{MDD}\sim\text{CL})} \times \text{DW}_{(\text{MDD})}$$

N = number of deaths;
L = standard life expectancy at age of death

P = number of prevalent cases;
DW = disability weight

Fig 1. Modified disability-adjusted life years (DALY) model for calculating the burden of co-morbid conditions. Adapted from Ton *et al* (2015) [24].

<https://doi.org/10.1371/journal.pntd.0007092.g001>

[30] were performed in Arabic and English, along with back referencing of relevant articles and a grey literature search. The search strategy accounted for common terms and abbreviations for cutaneous leishmaniasis (e.g. “CL” and “cutaneous leishmaniasis”), and combined these with key words for major depressive disorder and its symptoms, as well as general psychological impact (e.g. “psych*”, “major depressive disorder”, “distress”). We included all relevant psychological studies in CL patients and those with reliable knowledge of their experiences (i.e. their caregivers and their care providers) (Fig 2). As such, community studies were excluded from our final analysis except to further contextualise our findings. Please see S1 Appendix for further details of the search strategy and individual terms queried. Please see S2 Appendix for our inclusion and exclusion criteria, and S3 Appendix for the reasons for excluding studies from final analysis.

Results

Estimating major depressive disorder co-morbidity in cutaneous leishmaniasis

Twenty-nine studies were included in the final analysis of the psychosocial impact of CL (see S4 Appendix). The large majority (25/29) of studies were based in middle-income countries (18/29 UMIC, 7/29 LMIC) [32]. Similarly, most studies took place in the highest burden world regions (12/29 in the Eastern Mediterranean Region (EMR) and 11/29 in the Americas Region (AMR)), and included 11 of the 50 highest burden countries for CL in the world [9].

Studies that quantified an MDD diagnosis or symptoms using both validated (e.g. SCID-1; BDI) and unvalidated tools (e.g. self-reported depression symptoms) were used to determine rates of co-morbid MDD in both aCL and iCL (See Table 1). Additional quality of life, stigma, socioeconomic, and qualitative studies were used to generate an estimate of subclinical “distress” as per the staged model of depression (see Tables 2 and 3).

A diagnosis of MDD was consistently reached within the mean or one standard deviation of the mean in CL patients [33,34,36,38], equating to MDD rates of 30–50%. Meanwhile, quantification of symptoms of MDD mostly relied upon self-reporting. As such, symptoms of low




Fig 2. Prisma flowchart. [31].

<https://doi.org/10.1371/journal.pntd.0007092.g002>

mood and depression in CL patients ranged from 12.5–90.9% [34,40–45] aCL patients had significantly higher rates of MDD compared to controls in both children and adults [36] aCL was also found on multivariate analysis to be an independent risk factor for mental disorder in the primary care setting [33]. It is therefore unlikely that these results are a product of significant selection bias.

Equally, whilst rates of MDD were not measured for children with iCL, significantly higher rates of MDD were found in adults compared to controls. iCL patients were also at significantly higher suicide risk than controls [34]. In the only study to measure co-morbid MDD in both aCL and iCL, CL scarring was associated with non-statistically significantly higher MDD scores [38]. These findings are important, as considerably more patients are in the inactive (scarring) phase of CL than in the active phase. Although the data suggest that rates of MDD in iCL are at least equal to those found in aCL patients, the majority of studies (16/29) focused exclusively on aCL.

More broadly, quality of life was found to be significantly decreased in CL patients compared with controls. Stigma was a characteristic feature of CL in most quantitative and qualitative studies, whilst psychological distress was found to be between 50–90% [46,55]. Similarly, issues of disfigurement and reduced capacity to work affected the majority of sufferers (see Table 2). Interestingly, the psychological burden extended to CL caregivers, who were also

Table 1. Quantitative studies: MDD diagnosis and symptoms (validated and non-validated measures).

Author (Year)	Country (WHO Region)	Economic Development	Sample size	Sex	Age	Lesion location	Disease activity	MDD measure	Results	Interpretation
MDD diagnosis: Validated measure										
Simsek <i>et al</i> (2008) [33]	Turkey (EUR)	UMIC	64 (8 CL; 56 non-CL primary care)	100% F (Overall)	30 (Overall)	-	aCL	SCID-I (mental disorder)	CL: 53.3% Non-CL: 24.1%	aCL: independent risk factor for mental disorder; MDD most prevalent mental disorder; Multiple mental disorders common
Torkashvand <i>et al</i> (2016) [34]	Iran (EMR)	UMIC	160 (80 iCL; 80 former CL, no iCL)	43.1% F (Overall)	31.01 mean (Overall)	50% face; 50% rest of body	iCL	BDI	BDI (mean): Face: 11.66 ± 15.38 Body: 11.64 ± 14.11 No scar: 3.82 ± 8.09	0–13: Minimal 14–19: Mild 20–28: Moderate 29–63: Severe [35] BDI severity: Face: mild = 12.2%; mod = 4.9%; sev = 17.1%) Body: mild = 7.7%; mod = 15.4%; sev = 12.8% No scar = 3.8%; mod = 6.3%; sev = 2.5%
Turan <i>et al</i> (2015) [36]	Turkey (EUR)	UMIC	94 (54 CL; 40 healthy controls)	54% F (CL); 50% F (Control)	7–12; 13–18	65% face	aCL	CDI (Also QoL; see below)	7–12 (mean): aCL: 9.72 ± 6.11 Control: 4.5 ± 3.83 8–13 (mean): aCL: 14.25 ± 4.76 Control: 4.50 ± 2.46	Clinical cut-off: 13 Community cut-off: 19 [37] 8–13: Over 50% met clinical cut-off; those within 1 SD of mean met community cut-off. Patients aged 7–12: Those within 1 SD of mean met clinical cut-off; those within 2 SD met community cut-off Significantly higher than control at both age groups
Yanik <i>et al</i> (2004) [38]	Turkey (EUR)	UMIC	99 (33 iCL; 33 aCL; 33 healthy controls)	50.5% F (Overall)	18 (Overall)	70% face 30% UL (Overall)	aCL/ iCL	HADS-D (Also QoL; see below)	Mean aCL: 7.24 ± 3.91 Mean iCL: 8.67 ± 3.83 Mean control: 5.76 ± 4.01	Mild: 8–10 Moderate: 11–14; Severe: 15–21 [39] aCL: Mean score on cusp of mild MDD; those within 1 SD of mean met cut-off for moderate MDD iCL: Over 50% met cut-off for mild MDD; those within 1 SD of mean met cut-off for moderate MDD Depression rates significantly higher CL vs control
MDD symptoms: Validated measure										

(Continued)

Table 1. (Continued)

Author (Year)	Country (WHO Region)	Economic Development	Sample size	Sex	Age	Lesion location	Disease activity	MDD measure	Results	Interpretation
Honório <i>et al</i> (2016) [40]	Brazil (AMR)	UMIC	44	54.5% F	51.8	-	aCL	WHO-QoL Bref	Q26 Negative feelings (blue mood, anxiety, despair, depression) 90.9%	Frequency: 18.18% always; 43.18% very often; 20.45% quite often; 9.09% seldom; 9.1% never
Hu <i>et al</i> (2015) [41]	Suriname (AMR)	UMIC	163	8.3% F 7.6% F	7 day: 33 (median) 3 day: 30 (median)	7 day: 10.7% face 13 day: 7.7% face	aCL	EQ-5D (Also QoL; see below))	Depression/ Anxiety: Pre-treatment: 50.6% (7 day and 3 day) Post-treatment (6 wks): 7 day: 2.9; 3 day: 9.4%	Significantly reduced symptoms of anxiety and depression with treatment (both 3- and 7-day regimes)
Torkashvand <i>et al</i> (2016) [34]	Iran (EMR)	UMIC	160 (80 iCL; 80 former CL, no iCL)	43.1% F (Overall)	31.01 mean (Overall)	50% face; 50% rest of body	iCL	BSQ	BSQ (mean): Face: 4.73 ± 9.59 Body: 5.89 ± 8.91 No scar: 1.22 ± 3.47	Suicide risk level: Face: never = 78.0%; low = 4.9%; high = 17.1% Body: never = 61.5%; low = 12.8%; high = 25.6% No scar: never = 87.5%; low = 10.0%; high = 2.5%
MDD diagnosis/symptoms: Non-validated measure										
Al-Kamel (2017) [42]	Yemen (EMR)	LMIC	11	90.91% F	29.4 (mean)	38.5% UL 61.5% face	aCL 72.7% iCL 18.2% MCL 9.1%	Depression	27.3%	Self-reported depression rates not affected by presence of MCL
Bastidas <i>et al</i> (2008) [43]	Venezuela (AMR)	UMIC	17	58.8% F	25–34 mode	-	aCL/ iCL	Low mood	Total: 58.8% F: 100% M: 0%	Marked sex difference
Pacheco <i>et al</i> (2017) [44]	Brazil (AMR)	UMIC	24	62.5% F	38.8	100% exposed	aCL	Sadness, depression, low mood	Total: 12.5% (F: 33.3%; M: 0%)	Marked sex difference
Semeneh (2012) [45]	Ethiopia (AFR)	LIC	10	50% F	29.3	100% face	aCL 30% iCL 70%	High depression	30%	

BDI = Beck Depression Inventory; BSS = Beck Scale for Suicidal Ideation; CDI = Children’s Depression Inventory; EQ-5D = Euro-QoL-5 Dimensions; HADS-D = Hospital Anxiety and Depression Scale–Depression; LIC = Low Income Country; LMIC = Lower-Middle Income Country; SCID-I = Systematic Clinical Interview for Depression– 1st version; UMIC = Upper-Middle Income Country; WHO-QoL Bref = World Health Organization Quality of Life Short

<https://doi.org/10.1371/journal.pntd.0007092.t001>

found to have significantly elevated depression rates [36] and diminished quality of life [36,49] compared to controls.

Overall, CL is associated with a high degree of psychological morbidity irrespective of country, age, and disease activity. We present two other important patient- and disease-specific variables considered during our analysis: patient sex and lesion location. These were chosen due to multiple reports linking them with increased psychosocial impact. Indeed, despite findings of qualitative studies that facial lesions are the most psychologically damaging [42,45,63,67],

Table 2. Quantitative studies: Quality of life, psychological distress, stigma, socioeconomic impact studies.

Author (Year)	Country (WHO Region)	Economic Development	Sample size	Sex	Age	Lesion location	Disease activity	Measure	Results	Interpretation
Quality of life										
Chahed <i>et al</i> (2016) [46]	Tunisia (EMR)	LMIC	41	100% F	85% <30	93% face 54% rest of body	iCL	WHO-QoL Bref	Social relationships: 63.0 Psychological: 52.6 Social: 61.8 Environmental: 47.8 Total: 56.3	Psychological QoL on the verge of significant correlation with PLSI (p <0.087)
Elsaie <i>et al</i> (2017) [47]	Egypt (EMR)	LMIC	12	16.7% F	32	- (almost all exposed)	aCL	DLQI	Pre-treatment: 12.67 Post-treatment: 4.25	Pre-treatment: very large impact [48] Post-treatment: small impact [48] Significant reduction in all domains of QoL
Handjani <i>et al</i> (2013) [49]	Iran (EMR)	UMIC	50 (5 CL; 10 Psoriasis; 15 Vitiligo; 20 Pemphigus)	54% F (Overall)	42 (Overall)	-	aCL	FDLQI	Mean CL: 12.00 ± 4.80 Mean Psoriasis: 14.70 ± 5.01 Mean Vitiligo: 14.40 ± 5.08 Mean Pemphigus: 15.45 ± 4.70	Main concern (CL) is time spent looking after partner/relative (40%)
Honório <i>et al</i> (2016) [40]	Brazil (AMR)	UMIC	44	54.5% F	51.8	-	aCL	WHO-QoL Bref	Social relationships: 74.62 Psychological: 70.55 Physical: 61.85 Environment: 59.80 Total: 66.70	Q1-2: 81.82% rated QoL good or very good
Hu <i>et al</i> (2015) [41]	Suriname (AMR)	UMIC	163	8.3% F 7.6% F	7 day: 33 (median) 3 day: 30 (median)	7 day: 10.7% face 13 day: 7.7% face	aCL	Skindex-29	Pre-treatment 7 day: 28.4 3 day: 31.0 Post-treatment 7 day and 3 day: 1.7	Significant improvement post-treatment in both 3- and 7-day trials Mean pre-treatment score for both cohorts equates to moderate QoL impact (25–49.9) [50]
Nilforoushzadeh <i>et al</i> (2010) [51]	Iran (EMR)	UMIC	80	100% F	- (>10)	-	aCL	DLQI	Drug + Psychotherapy Before: 10.6 ± 5.7 After: 7.7 ± 4.6 Drug alone Before: 10.0 ± 5.1 After: 11.0 ± 5.1	Before treatment QoL: No impact: 0% Small impact: 26.125% Moderate impact: 46.125% Very large impact: 25.0% Extremely large impact: 2.5%

(Continued)

Table 2. (Continued)

Author (Year)	Country (WHO Region)	Economic Development	Sample size	Sex	Age	Lesion location	Disease activity	Measure	Results	Interpretation
Ranawaka <i>et al</i> (2014) [52]	Sri Lanka (SEAR)	LMIC	146	28% F	31 (median)	45% UL 25% face 20% LL 10% trunk	aCL	DLQI	Mean: 5.58	Severity: No impact: 21.0% Small impact: 34.2% Moderate impact: 30.8% Very large impact: 13.3% Extremely large impact: 0.7%
Toledo <i>et al</i> (2013) [53]	Brazil (AMR)	UMIC	20	15% F	45.6	40% exposed areas	aCL	DLQI	Mean: 9.75	Severity: No impact: 0% Small impact: 30% Moderate impact: 30% Very large impact: 40% Extremely large impact: 0%
Turan <i>et al</i> (2015) [36]	Turkey (EUR)	UMIC	94 (54 CL; 40 healthy controls)	54% F (CL); 50% F (Control)	7–12; 13–18	65% face	aCL	PedQoL	7–12 aCL: 81.31 ± 11.39 Control: 91.83 ± 4.76 13–18 aCL: 74.99 ± 13.95 Control: 80.34 ± 4.74	Young aCL patients significantly worse QoL than controls Parents' QoL scores also significantly lower than controls
Vares <i>et al</i> (2013) [54]	Iran (EMR)	UMIC	124	62.9% F	36.9 (mean)	70% UL 15% face 10% LL	aCL (94%) iCL (6%)	DLQI	5.87 ± 5.96	Severity: No impact: 26.8% Small impact: 30.5% Moderate impact: 24.2% Very large impact: 15.3% Extremely large impact: 3.2%
Yanik <i>et al</i> (2004) [38]	Turkey (EUR)	UMIC	99 (33 iCL; 33 aCL; 33 healthy controls)	50.5% F (Overall)	18 (Overall)	70% face 30% UL (Overall)	aCL/ iCL	DQLI	aCL: 34.77 ± 8.47 iCL: 24.11 ± 8.56	QoL better in aCL vs iCL Moderate correlation with HADS-D and DQLI ($r_s = 0.291$)
Psychological distress										

(Continued)

Table 2. (Continued)

Author (Year)	Country (WHO Region)	Economic Development	Sample size	Sex	Age	Lesion location	Disease activity	Measure	Results	Interpretation
Bennis <i>et al</i> (2017) [55]	Morocco (EMR)	LMIC	86	42.2% F	17.7	-	aCL/ iCL	Psychosocial impact	“Yes” = 48.8% “Maybe” = 40.7% “No” = 10.5%	Somewhat town-dependent: 13% “no psychosocial impact” in one town; 7% “no psychosocial impact” in another town
Chahed <i>et al</i> (2016) [46]	Tunisia (EMR)	LMIC	41	100% F	85% <30	93% face 54% rest of body	iCL	PLSI	PLSI: 9.5 ± 6.7	A score of 10 + denotes a high degree of stress in psoriatic patients [56]
Stigma, disfigurement, and socio-economic impact										
Al-Kamel (2017) [42]	Yemen (EMR)	LMIC	11	90.91% F	29.4	38.5% UL 61.5% face	aCL 72.7% iCL 18.2% MCL 9.1%	Stigma	Social: 63.64% Aesthetic: 63.64% Psychological: 72.73%	1+ forms of stigma: 90.91% (1 form: 27.27% 2 forms: 18.18% 3 forms: 45.45%)
Abazid <i>et al</i> (2012) [57]	Syria (EMR)	LMIC	70	59% F	32.3	-	aCL/ iCL	Disfigurement	32.9%	Worst effects of CL: Appearance of aCL (68.6%) and permanence of iCL (32.9%)
Chahed <i>et al</i> (2016) [46]	Tunisia (EMR)	LMIC	41	100% F	85% <30	93% face 54% rest of body	iCL	Exclusion Body image Worse marital prospects	73% 58% 75% (for M); 59% (for F)	
Fernando <i>et al</i> (2010) [58]	Sri Lanka (SEAR)	LMIC	120	27% F	31.6	F: 56% face M: 41% UL	aCL	Isolation and social stigma Absent/ unable to work	18% M 25% F 55% M; 40% F	Worse with facial lesions
Pacheco <i>et al</i> (2017) [44]	Brazil (AMR)	UMIC	24	62.5% F	38.8	100% exposed	aCL	Social discrimination Family discrimination	Total: 37.5% (F 66.6%; M 20%) Total: 20.8% (F: 55.5%; M 0%)	Marked gender differences
Ramdas <i>et al</i> (2016) [59]	Suriname (AMR)	UMIC	205	10.7% F	30–39 mode	- (face rare)	aCL	Shame, disgust Enacted stigma	18.5% 16%	Author reports low stigma due to rarity of facial lesions
Reithinger <i>et al</i> (2005) [60]	Afghanistan (EMR)	LIC	83 (parents of affected)	100% F	-	-	aCL/ iCL	Disfigurement	54% felt disfigured children by lesions/scars, treatment, exclusion	
Ruoti <i>et al</i> (2013) [61]	Paraguay (AMR)	UMIC	25	28% F	49	-	CL/ MCL	Shame	12.5%	
Semeneh (2012) [45]	Ethiopia (AFR)	LIC	10	50% F	29.3	100% face	aCL 30% iCL 70%	Disgrace/ despair Shame Low self-esteem, guilt	80% 40% 70%	

(Continued)

Table 2. (Continued)

Author (Year)	Country (WHO Region)	Economic Development	Sample size	Sex	Age	Lesion location	Disease activity	Measure	Results	Interpretation
Weigel <i>et al</i> (1994) [62]	Ecuador (AMR)	UMIC	208	46.6% F	35.8	-	aCL/ iCL	Impact on ability to work Low self-esteem	iCL: 68.9% aCL: 61.3% Total: 67.1% iCL: 82.7% aCL: 76.9% Total: 81.3%	Men significantly more than women Woman significantly more than men
Yanik <i>et al</i> (2004) [38]	Turkey (EUR)	UMIC	99 (33 iCL; 33 aCL; 33 healthy controls)	50.5% F (Overall)	18 (Overall)	70% face 30% UL (Overall)	aCL/ iCL	BIS	aCL: 17.15 ± 11.07 iCL: 21.0 ± 8.16 Control: 38.69 ± 6.37	Body image significantly reduced; moderately correlated with HADS-D ($r_s = 0.256$)

DLQI = Dermatology Life Quality Index; DQLI = Dermatology Quality of Life Index; FDLQI = Family Dermatology Life Quality Index; PedQoL = Pediatric Quality of Life; PLSI = Psoriasis Life Severity Index

<https://doi.org/10.1371/journal.pntd.0007092.t002>

none of the four quantitative studies [34,46,52,54] providing subgroup analysis demonstrated a statistically significant association with facial lesions and worsening psychological outcomes. Moreover, facial iCL scars were actually associated with lower rates of depression and suicidality than those located on other parts of the body [34]. Instead, it may be more appropriate to differentiate the visibility of lesions in future studies.

A significant number of studies focused solely on women (5/29) on the basis that women are generally at greater risk of depression [17]. It is therefore important to consider possible sex differences in MDD rates given that men have more reported cases of CL than women in most endemic countries [4]. Interestingly, women-only studies were found to have comparable MDD rates as mixed sex studies, although differences in self-reported symptoms of MDD were noted in some countries [43,44]. The reasons for these findings could perhaps be explained by community [68], socio-economic [62], and qualitative studies [67]. For example, whilst women are commonly more concerned by bodily appearance and marital prospects, a roughly equal impact is placed upon men through incapacity to work and perform leadership responsibilities [52] due to the disease.

Based on the available evidence, we conservatively estimate that 70% of individuals with both active and inactive CL will experience some degree of psychological morbidity. This ranges from subclinical “distress” (50%) to clinical “disorder” (20%), in accordance with the staged model of depression [19]. As such, 30% of CL patients fall into the “wellness” category of the model, in view of regional differences in psychosocial impact [55,65] and the small number of countries and endemic communities in which CL is less stigmatizing [59] and perceived as less severe [69] (see Table 4).

Calculating the prevalence of inactive CL

The 2016 GBD Study provides CL prevalence estimates that account solely for aCL and that also include MCL within them unseparated. As such, the prevalence of inactive (scarring) CL has not been previously estimated, and is not incorporated formally into the GBD burden estimates for CL. The methodology for calculating the prevalence of inactive CL has been previously described [3]. In short, our calculations are derived from the latest reported aCL

Table 3. Qualitative studies.

Author (Year)	Country (WHO Region)	Economic Development	Sample size	Sex	Age	Lesion location	Disease activity	Results
Al-Kamel (2017) [38]	Yemen (EMR)	LMIC	11	90.91% F	29.4	38.5% UL 61.5% face	aCL 72.7% iCL 18.2% MCL 9.1%	Fear and social isolation common; Oldest patient (60yo) suggests stigma is age-related; Concerns about facial lesions and marital prospects
Alorfi (2016) [63]	Saudi Arabia (EMR)	HIC	21 (Health Workers; HW)	42.86% F	-	-	aCL/ iCL	Stigma from iCL noted by 8/21 HWs; 1/21 says no stigma Parental guilt at children being affected; All HWs agree CL has psych impact; main concern is iCL; 1/21 HW recounts suicidal ideation in patient; Low self-esteem and depression common; Fears regarding lack of effective treatment
Bennis <i>et al</i> (2017) [55]	Morocco (EMR)	LMIC	86	42.2% F	17.7	-	aCL/ iCL	Low self-esteem and diminished social value common; Marital prospects decreased; psychological impact can increase after treatment as scar remains; fear and worry concerning lack of treatment services
da Silva <i>et al</i> (2004) [64]	Brazil (AMR)	UMIC	8	100% F	-	-	aCL	Fearful for health; uncertain of treatment; feel trapped; worried about appearance
Guevara <i>et al</i> (2007) [65]	Venezuela (AMR)	UMIC	30 (Dermatologists, health inspectors/promoters, nurses, social workers)	-	-	-	aCL	All participants: patients express cultural significance of aCL and its psychological impact, but this is not registered by healthcare professionals due to strictly disease-focused, biomedical approach to CL Perception is location dependent. CL is seen either as a "sore", "leprosy", or a "bite". Differential impact depending on how it is perceived.
Martins (2014) [66]	Brazil (AMR)	UMIC	7	20% F	45	-	aCL	Strong social impact of aCL and iCL on work, church and school Fear, low self-esteem, depression, and isolation frequently seen
Ramdas <i>et al</i> (2016) [59]	Suriname (AMR)	UMIC	205	10.7% F	30–39 mode	- (face rare)	aCL	Social restrictions infrequent due to cohesiveness of local community and recognition of CL as a non-contagious disease
Reyburn <i>et al</i> (2000) [67]	Afghanistan (EMR)	LIC	84	54.8%	28	- (usually face/hands)	aCL	Males more affected in work and public life (religion, work), females more affected at home (cooking, hospitality); overall equal impact Most report stigmatisation; in some, strong feelings of shame Need to isolate CL sufferers developed into personal rejection; lack of personal contact particularly problematic for children Very rare for CL to stimulate more caring attitudes towards sufferers

(Continued)

Table 3. (Continued)

Author (Year)	Country (WHO Region)	Economic Development	Sample size	Sex	Age	Lesion location	Disease activity	Results
Semeneh (2012) [45]	Ethiopia (AFR)	LIC	10	50% F	29.3	100% face	aCL 30% iCL 70%	MDD symptoms (low self-esteem, hopelessness, sadness) very common; Poor QoL due to CL impact on SES, and lack of treatment services; Main concern is aCL, yet all left disfigured by iCL scar; Commonly insulted with local terms for both iCL and aCL; Vast majority experienced stigma, especially in aCL phase; Unaffected people favoured for work, especially if facial lesions; Marital rejection common, though some believe not a problem

AFR = African Region; AMR = Region of the Americas; EMR = Eastern Mediterranean Region; EUR = European Region; HIC = High Income Country; SEAR = South-East Asian Region

<https://doi.org/10.1371/journal.pntd.0007092.t003>

incidence data from WHO spanning 2006–2015 [70] that have been adjusted for underreporting [10,71] and the presence of MCL within them [72–74] (see Table 5). We assume zero CL-associated mortality and a life expectancy of 30 years with scarring; this is a conservative longevity estimate considering the life expectancy of at-risk populations in high burden countries [74] For further information on this methodology, please see S5 Appendix.

Estimating the severity of major depressive disorder co-morbidity in cutaneous leishmaniasis

GBD Studies differentiate the severity of episodes of MDD at three levels—mild, moderate, and severe—each with its own disability weight [22]. Therefore, it is necessary to calculate the severity of co-morbid MDD in CL patients to calculate the disability burden (YLD) component of the DALY.

In the studies we identified, the mean depression scores of CL patients equated to mild MDD, with moderate MDD scores being reached within one standard deviation in most studies. Furthermore, in a study of depression in inactive CL using Beck’s Depression Inventory, ~70% of cases with depression scored in “mild” severity [34]. Due to the relatively small sample sizes and difficulties in comparing MDD severity from different measurement tools, we used data from the 2010 GBD study on depressive disorders to help inform our estimates (see Table 6). In that study, the patient MDD cohort was classified accordingly: 72.7% with *Mild* severity; 16.5% with *Moderate* severity; and 10.8% with *Severe* MDD [22].

Table 4. Estimating the psychological impact of CL using the staged model of depression adapted from Patel (2017) [19].

Stage	Definition	CL estimate	References
Wellness	Absence of any sustained, distressing, emotional experiences	30%	[57–59, 61]
Distress	Mild to moderate distressing emotional experiences of relatively short duration	50%	[46, 47, 49, 51–55, 60, 62]
Major Depressive Disorder	Severely distressing experiences, lasting at least two to four weeks, with impairment of social functioning	20%	[33, 34, 36, 38, 40–45]
Recurrent Major Depressive Disorder	Unresponsive or relapsing depressive episodes		

<https://doi.org/10.1371/journal.pntd.0007092.t004>

Table 5. Estimating the prevalence of inactive CL.

	Active CL (GBD 2016) [18]	Inactive CL	Total
Ratio	~10	~90	100
Prevalence	4,320,000	33,883,900	38,203,900

<https://doi.org/10.1371/journal.pntd.0007092.t005>

Quantifying DALYs for major depressive disorder in cutaneous leishmaniasis

Applying the estimate for MDD severity to our prevalence estimates for cutaneous leishmaniasis, the following YLDs were calculated: 200,000 for active CL, and 1.7 million for inactive CL (combined total 1.9 million YLDs for CL) (see Table 7 and Table 8). We assumed no mortality burden associated with MDD co-morbid to cutaneous leishmaniasis, and as such our YLD figures equaled the overall DALY figures (see S6 Appendix for in-depth calculations). These figures only represent the impact of co-morbid MDD in this condition and do not account for the impact of other mental disorders such as anxiety disorders or the subclinical state of distress as per the staged model of depression [19].

Discussion

The results presented here challenge the most recent GBD estimates for the overall burden of CL given the prevalence of mental illness reported in the literature for the condition. We highlight the lack of reliable prevalence estimates on which GBD figures are based. We further emphasise that, despite the increased recognition of NTDs through their inclusion as a target within the UN Sustainable Development Goal (SDG) health targets, the burden of mental health associated with stigmatising and chronically disabling NTDs is not appropriately factored into the calculations of overall global mental health estimates. We stress the importance of residual disease on the continuing suffering of those with NTDs using the example of inactive CL.

Indeed, inclusion of iCL increases the CL prevalence estimate 10-fold, which substantially increases the CL disease burden in itself. However, factoring in the burden of co-morbid MDD for both aCL and iCL further increases its overall burden to 2.2 million DALYs. This is approximately eight times greater than the previous DALY estimate reported in the 2016 GBD study that accounted for aCL alone [76]; this is despite our conservative estimate of only a 30 years of life expectancy post-lesion acquisition (see Table 8). Significant increases in burden estimates were calculated previously for lymphatic filariasis [24], indicating that mental illness is grossly unaccounted for in the NTD GBD estimates.

These findings come at a crucial time for those affected by CL, a growing number of whom continue to be affected by war and displacement in current conflict zones. The inclusion of iCL into prevalence estimates for CL, we argue, is necessary to enact changes at the policy level that reflect the importance of CL to affected individuals and their communities. Moreover, the

Table 6. Estimating the severity of co-morbid MDD in cutaneous leishmaniasis.

Severity of MDD	Disability Weight ⁷⁵	Severity of MDD In 2010 GBD Study [22]
Mild	0.145	72.7%
Moderate	0.396	16.5%
Severe	0.658	10.8%

<https://doi.org/10.1371/journal.pntd.0007092.t006>

Table 7. Estimating the burden of Major Depressive Disorder in cutaneous leishmaniasis.

	Active CL*	Inactive CL	Total CL
Prevalence	4,320,000 [18]	33,883,900	38,203,900
Prevalence with MDD (%)	20%	20%	20%
Disability Weights (GBD 2016) [75]	0.145 (Mild MDD) 0.396 (Moderate MDD) 0.658 (Severe MDD)	0.145 (Mild MDD) 0.396 (Moderate MDD) 0.658 (Severe MDD)	0.145 (Mild MDD) 0.396 (Moderate MDD) 0.658 (Severe MDD)
YLDs (Co-morbid MDD alone)	208,932	1,687,065	1,895,997
YLLs (Co-morbid MDD alone)	0	0	0
DALYs (Co-morbid MDD alone)	208,932	1,687,065	1,895,997

<https://doi.org/10.1371/journal.pntd.0007092.t007>

studies we have highlighted show a clear benefit for psychological as well as physical therapies on quality of life [41,47,51] as well as rates of depression [41] in CL patients; sadly, inability to access any form of treatment is a commonly cited major concern for patients [45,55,63,64]. As such, there is a very clear opportunity for national NTD programmes and partner international NGOs to incorporate mental health care into their activities and to provide appropriate services to tackle this growing public health problem.

Overall, the stigma and depression linked to NTDs represent areas of global health that have only recently been highlighted [21]. From our literature review, the previous GBD estimates for depression (which predict depressive disorders as a leading cause of DALYs) do not incorporate MDD (or any other mental illness) associated with NTDs. Omitting NTDs from such consideration of global mental health burden is significant as NTDs have been estimated by WHO to affect over 1 billion (1 in 6) people worldwide [1].

Implications for future GBD studies

In the latest 2016 iteration of the GBD study, the psychological impact of CL scarring has been incorporated into the disease burden estimates for the first time via a modification of disability weights (DW) (IHME personal communication). As such, the disability burden of CL has increased from 41,500 [77] to 273,000 [18] YLDs. Despite this modification, relying upon DWs to capture the unique psychosocial aspects of NTDs has unfortunately led to some of the most stigmatising (namely CL and leprosy) diseases yielding some of the lowest disability (YLD) estimates of all the NTDs in past iterations [18,77–79]. CL is currently viewed as a “level two disfigurement”, meaning that its DW reflects “a visible physical deformity that causes others to stare and comment. As a result, the person is worried and has trouble sleeping and concentrating”. This corresponds to a DW of 0.067 in GBD 2016, where 0 indicates perfect health and 1

Table 8. Overall DALY estimates for cutaneous leishmaniasis (aCL and iCL).

	Active CL	Inactive CL	Total
Physical health DALYs (GBD 2016)²⁶	273,000*	-	273,000
Co-morbid MDD DALYs	208,932*	1,687,065	1,895,997
Physical health + Co-morbid MDD DALYs	481,932*	1,687,065	2,168,997

*GBD estimate includes MCL

<https://doi.org/10.1371/journal.pntd.0007092.t008>

indicates death [75]. Thus, we can be confident that our findings represent an unrecognized mental disease burden of CL.

Instead, we strongly recommend that inactive (scarring) CL be included with active CL infection in future CL prevalence estimates, and that MCL and aCL estimates be presented separately for further information. We have shown that with inactive CL, such a large increase in prevalence (10-fold higher) and burden of co-morbid MDD (8-fold increase) is not sufficiently accounted for by simply altering the DWs for active CL given the evidence of mental illness in patients with residual scarring. As we have only included the “disorder” stage of depressive burden in our YLD estimates, our estimate of CL-related distress (50%) using the staged model approach to depression is not accounted for. Here adjustments to DWs for both aCL and iCL would be justified, as a large proportion of affected individuals with both forms of CL experience some degree of quantifiable distress or socially adverse consequences.

Finally, it is important to highlight that the 2016 GBD Study estimates of aCL incidence [18] are almost half those of previously accepted incidence estimates published in 2012 [71]. This is despite the marked increase in CL incidence due to ongoing conflict and displacement in the Middle East [15]. Similarly, our aCL burden estimates are based upon the 2016 GBD Study estimates of aCL prevalence to allow for comparisons to be made. However, it is unclear why these prevalence estimates are almost seven times lower than the annual incidence of aCL [18] when the majority of cases of aCL self-heal within 6–12 months [2]. For these reasons, we did not include GBD estimates in our calculations of iCL prevalence.

Study limitations

Although our study is the first to generate prevalence estimates of inactive (scarring) CL, we were cautious of the life span of patients with iCL lesions, which is currently unknown. Whilst the majority of CL infections occur in older children and young adults [4] we took a conservative approach to our iCL prevalence estimates by assuming just 30 years lived with residual scars. Nevertheless, given that the majority of aCL cases occur in the young and working adult populations, this figure could be significantly higher. We also conservatively assume no mortality burden with CL, yet suicidal risk and ideation has been noted in both aCL and iCL patients [34,63].

Secondly, we acknowledge our failure to include prevalence and isolated burden estimates for co-morbid MDD in MCL. As discussed, MCL prevalence (and YLD burden) has not been separated from that of aCL in GBD Studies. A further complicating factor is the mortality rate of MCL, which has not been established and consequently prevented us from generating reliable MCL prevalence estimates from WHO incidence data. Nevertheless, the experience of shame in CL patients [45,59] was surprisingly higher than that found in a study of mixed MCL and CL patients [61]. However, in a study of MCL patients alone [80], notably those with severe disease, rates of social exclusion and reduced quality of life were comparable to those found in CL patients [45,52,54,62]. It is possible that the prevalence of co-morbid MDD in MCL patients is similar to that of aCL patients (~20% of cases), meaning that our aCL burden estimates may be relatively unaffected by the presence of MCL cases within them.

This is the first study to estimate the burden of a co-morbid mental disorder in aCL and iCL. One major limitation of our estimates is the evidence underpinning them. We recognize that our 29 studies represent only a relatively small proportion of the global CL caseload. Nevertheless, our systematic literature review has identified the majority of evidence of psychological impact in CL patients to date, and doubled the evidence of previous recent attempts [81]. Moreover, these studies represent a range of geographically diverse populations across several levels of economic development. In our analysis, studies quantifying MDD using robust and

internationally recognised criteria (i.e. DSM) were given the most weight in generating our final estimates of MDD co-morbid to CL. We were also selective and chose to only utilize studies of CL patients and their care providers. In order to minimize the effects of bias we accounted for patient- and disease-specific variables such as sex, age, lesion location, and country of study. As results for co-morbid MDD were comparable when these variables changed, we were confident that none of these variables could have significantly biased our overall estimates.

Finally, whilst depressive disorders represent the most prevalent form of mental disorder worldwide, CL patients are affected by a range of other mental disorders, which have not been included in our estimates. Indeed, CL patients may be at even greater risk of multiple mental disorders [33]. These include generalised anxiety disorder, which may predominate in the active CL phase [36,38] post-traumatic stress disorder [33] and mixed anxiety and depressive disorder [41], the latter of which is not independently considered within the GBD framework at present.

Conclusion

Social stigma, disfigurement, and patient suffering are some of the most identifiable features of NTDs, as emphasized by the case of cutaneous leishmaniasis. However, the suffering of those with active infection as well as those who remain disfigured by NTDs post-infection is not adequately factored into NTD programmes or burden estimates. We reason that there is value in striving for both goals by placing the individual at the centre of such programmes to achieve the holistic care of individuals affected by NTDs. After all, focusing solely on the disease alone ignores the characteristic disability associated with NTDs such as cutaneous leishmaniasis, leprosy, and filariasis, and risks leaving affected individuals behind.

Supporting information

S1 Appendix. Search strategies.

(DOCX)

S2 Appendix. Inclusion/exclusion criteria.

(DOCX)

S3 Appendix. Reasons for exclusion following full-text review.

(DOCX)

S4 Appendix. Summary of CL papers.

(DOCX)

S5 Appendix. Calculating the prevalence of active and inactive CL.

(DOCX)

S6 Appendix. Quantifying the burden of co-morbid MDD in cutaneous leishmaniasis.

(DOCX)

S7 Appendix. PRISMA checklist.

(DOCX)

Author Contributions

Conceptualization: Álvaro Acosta-Serrano, David H. Molyneux.

Data curation: Freddie Bailey, José Antonio Ruiz-Postigo, Jorge Alvar.

Formal analysis: Freddie Bailey, Karina Mondragon-Shem.

Funding acquisition: David H. Molyneux.

Investigation: Freddie Bailey, David H. Molyneux.

Methodology: Freddie Bailey.

Resources: Álvaro Acosta-Serrano, David H. Molyneux.

Supervision: Álvaro Acosta-Serrano, David H. Molyneux.

Validation: Freddie Bailey, Karina Mondragon-Shem, Lee Rafuse Haines, Amina Olabi, Ahmed Alorfi, José Antonio Ruiz-Postigo, Jorge Alvar, Peter Hotez, Emily R. Adams, Iván D. Vélez, Waleed Al-Salem, Julian Eaton, Álvaro Acosta-Serrano, David H. Molyneux.

Visualization: David H. Molyneux.

Writing – original draft: Freddie Bailey, David H. Molyneux.

Writing – review & editing: Freddie Bailey, Karina Mondragon-Shem, Lee Rafuse Haines, Amina Olabi, Ahmed Alorfi, José Antonio Ruiz-Postigo, Jorge Alvar, Peter Hotez, Emily R. Adams, Iván D. Vélez, Waleed Al-Salem, Julian Eaton, Álvaro Acosta-Serrano, David H. Molyneux.

References

1. Molyneux DH, Savioli L, Engels D. Neglected tropical diseases: progress towards addressing the chronic pandemic. *Lancet*. 2017; 389(10066):312–25. [https://doi.org/10.1016/S0140-6736\(16\)30171-4](https://doi.org/10.1016/S0140-6736(16)30171-4) PMID: 27639954
2. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous Leishmaniasis. *Lancet Infect Dis*. 2007; 7(9):581–96. [https://doi.org/10.1016/S1473-3099\(07\)70209-8](https://doi.org/10.1016/S1473-3099(07)70209-8) PMID: 17714672
3. Bailey F, Mondragon-Shem K, Hotez P, Ruiz-Postigo JA, Al-Salem W, Acosta-Serrano Á et al. A new perspective on cutaneous leishmaniasis—Implications for global prevalence and burden of disease estimates. *PLoS Negl Trop Dis*. 2017; 11(8):e0005739. <https://doi.org/10.1371/journal.pntd.0005739> PMID: 28796782
4. World Health Organization. Control of the leishmaniasis: Report of a meeting of the WHO Expert Committee on the Control of Leishmaniasis, Geneva, 22–26 March 2010. *World Health Organ Tech Rep Ser*. 2010; 949:186.
5. Mendonça Mitzi G, de Brito Maria EF, Rodrigues Eduardo HG, Valdir B, Jardim Márcio L, Abath Frederico GC. Persistence of *Leishmania* Parasites in Scars after Clinical Cure of American Cutaneous Leishmaniasis: Is There a Sterile Cure? *J Infect Dis*. 2004; 189(6):1018–1023. <https://doi.org/10.1086/382135> PMID: 14999605
6. Handman E. *Leishmania* vaccines: old and new. *Parasitol Today*. 1997; 13(6):236–8. PMID: 15275077
7. Bern C, Maguire JH, Alvar J. Complexities of Assessing the Disease Burden Attributable to Leishmaniasis. *PLoS Negl Trop Dis*. 2008; 2(10):e313. <https://doi.org/10.1371/journal.pntd.0000313> PMID: 18958165
8. Deribe K. Neglected tropical disease targets must include morbidity. *Lancet Glob Health*. 2015. 3(10):e596. [https://doi.org/10.1016/S2214-109X\(15\)00185-0](https://doi.org/10.1016/S2214-109X(15)00185-0) PMID: 26385299
9. Karimkhani C, Wanga V, Coffeng LE, Naghavi P, Dellavalle RP, Naghavi M. Global burden of cutaneous leishmaniasis: a cross-sectional analysis from the Global Burden of Disease Study 2013. *Lancet Infect Dis*. 2016; 16(5):584–91. [https://doi.org/10.1016/S1473-3099\(16\)00003-7](https://doi.org/10.1016/S1473-3099(16)00003-7) PMID: 26879176
10. Mathers CD, Ezzati M, Lopez AD. Measuring the Burden of Neglected Tropical Diseases: The Global Burden of Disease Framework. *PLoS Negl Trop Dis*. 2007; 1(2):e114. <https://doi.org/10.1371/journal.pntd.0000114> PMID: 18060077
11. Guthmann JP, Calmet J, Rosales E, Cruz M, Chang J, Dedet JP. Patients' associations and the control of leishmaniasis in Peru. *Bull World Health Org*. 1997; 75(1):39–44. PMID: 9141749
12. Jahan S, Al-Saigul AM, Nimir SE, Mustafa AS. Priorities for primary health care research in Qassim, central Saudi Arabia. *Saudi Med J*. 2014; 35(3):298–303. PMID: 24623211

13. Carrillo-Bonilla LM, Trujillo JJ, Álvarez-Salas L, Vélez-Bernal ID. Study of knowledge, attitudes, and practices related to Leishmaniasis: evidence of government neglect in the Colombian Darién. *Cad Saúde Pública Rio de Janeiro*. 2014; 30(10):2134–2144.
14. Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. *Trends Parasitol*. 2006; 22(12):552–7. <https://doi.org/10.1016/j.pt.2006.09.004> PMID: 17023215
15. Du R, Hotez PJ, Al-Salem WS, Acosta-Serrano Á. Old World Cutaneous Leishmaniasis and Refugee Crises in the Middle East and North Africa. *PLoS Negl Trop Dis*. 2016; 10(5):e0004545. <https://doi.org/10.1371/journal.pntd.0004545> PMID: 27227772
16. Hayani K, Dandashli A, Weisshaar E. Cutaneous leishmaniasis in Syria: clinical features, current status and the effects of war. *Acta Derm Venereol*. 2015; 95(1):62–6. <https://doi.org/10.2340/00015555-1988> PMID: 25342106
17. WHO. Depression and Other Common Mental Disorders: Global Health Estimates. WHO. 2017. Available from: http://www.who.int/mental_health/management/depression/prevalence_global_health_estimates/en/
18. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet*. 2017; 390(10100):1211–1259. [https://doi.org/10.1016/S0140-6736\(17\)32154-2](https://doi.org/10.1016/S0140-6736(17)32154-2) PMID: 28919117
19. Patel V. Talking sensibly about depression. *PLoS Med*. 2017; 14(4):e1002257. <https://doi.org/10.1371/journal.pmed.1002257> PMID: 28376089
20. Litt E, Baker MC, Molyneux D. Neglected tropical diseases and mental health: a perspective on comorbidity. *Trends Parasitol*. 2012; 28(5):195–201. <https://doi.org/10.1016/j.pt.2012.03.001> PMID: 22475459
21. de Vlas SJ, Stolk WA, le Rutte EA, Hontelez JAC, Bakker R, Blok DJ et al. Concerted Efforts to Control or Eliminate Neglected Tropical Diseases: How Much Health Will Be Gained?. *PLoS Negl Trop Dis*. 2016; 10(2):e0004386. <https://doi.org/10.1371/journal.pntd.0004386> PMID: 26890362
22. Ferrari AJ, Charlson FJ, Norman RE, Patten SB, Freedman G, Murray CJL et al. Burden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010. *PLoS Med*. 2013; 10(11):e1001547. <https://doi.org/10.1371/journal.pmed.1001547> PMID: 24223526
23. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. *Lancet*. 2007; 370(9590):851–858. [https://doi.org/10.1016/S0140-6736\(07\)61415-9](https://doi.org/10.1016/S0140-6736(07)61415-9) PMID: 17826170
24. Ton TGN, Mackenzie C, Molyneux DH. The burden of mental health in lymphatic filariasis. *Infect Dis Pov*. 2015; 4:34.
25. Ovid MEDLINE [Internet]. Ovid. Available from: <http://www.ovid.com/site/catalog/databases/901.jsp>.
26. Embase [Internet]. Ovid. Available from: <http://www.ovid.com/site/catalog/databases/903.jsp>.
27. Global Health [Internet]. Ovid. Available from: <http://www.ovid.com/site/catalog/databases/30.jsp>.
28. PsycINFO [Internet]. Ovid. Available from: <http://www.ovid.com/site/catalog/databases/139.jsp>.
29. LILACS EN [Internet]. BV Salud. Available from: <http://lilacs.bvsalud.org/en/>.
30. Google Scholar [Internet]. Google. Available from: <https://www.scholar.google.com>.
31. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med*. 2009; 6(7):e1000097. <https://doi.org/10.1371/journal.pmed.1000097> PMID: 19621072
32. Bank World. Countries: Data. World Bank. 2018. Available from: <https://data.worldbank.org/country>.
33. Simsek Z, Ak D, Altindag A, Günes M. Prevalence and predictors of mental disorders among women in Sanliurfa, Southeastern Turkey. *J Pub Health*. 2008; 30(4):487–493.
34. Torkashvand F, Rezaeian M, Sheikh Fathollahi M, Mohammadreza Khaninezhad S, Hatami P, Bidaki R. A Survey on Psychiatric Disorders in Patients Improved Cutaneous Leishmaniasis In the city of Rafsanjan in 2014. *J Rafsanjan Univ Med Sci*. 2016; 14(10):879–894.
35. Jackson-Koku G. Beck Depression Inventory. *Occupat Med*. 2016; 66(2):174–175.
36. Turan E, Kandemir H, Yeşilova Y, Ekinci S, Tanrikulu O, Kandemir SB et al. Assessment of the psychiatric morbidity and quality of life in children and adolescents with cutaneous leishmaniasis and their parents. *Postep Derm Alergol*. 2015; 32(5):344–348.
37. Friedberg RD, Sinderman SA. CDI Scores in Pediatric Psychiatric Inpatients: A Brief Retrospective Static Group Comparison. *Dep Res Treat*. 2011; 2011:134179.
38. Yanik M, Gurel MS, Simsek Z, Kati M. The psychological impact of cutaneous leishmaniasis. *Clin Exp Dermatol*. 2004; 29(5):464–467. <https://doi.org/10.1111/j.1365-2230.2004.01605.x> PMID: 15347324

39. Stern AF. The Hospital Anxiety and Depression Scale. *Occupat Med.* 2014; 64(5):393–394.
40. Honório IM, Cossul MU, Bampi LNS, Baraldi S. Quality of life in people with cutaneous leishmaniasis. *Rev Bras Promoç Saúde Fortaleza.* 2016; 29(3):342–349.
41. Hu RVPF, Straetemans M, Kent AD, Sabajo LOA, de Vries HJC, Lai A Fat RFM. Randomized Single-Blinded Non-inferiority Trial Of 7 mg/kg Pentamidine Isethionate Versus 4 mg/kg Pentamidine Isethionate for Cutaneous Leishmaniasis in Suriname. *PLoS Negl Trop Dis.* 2015; 9(3):e0003592. <https://doi.org/10.1371/journal.pntd.0003592> PMID: 25793773
42. Al-Kamel MA. Stigmata in cutaneous leishmaniasis: Historical and new evidence-based concepts. *Our Dermatol Online.* 2017; 8(1):81–90.
43. Bastidas GA, Díaz B. Prácticas y conocimientos populares sobre leishmaniasis tegumentaria americana (LTA) en un área endémica de Cojedes, Venezuela. *Fermentum Rev Venez Sociol y Antropol.* 2008; 18(53):634–655.
44. Pacheco SJB, Martins ACdC, Pimentel MIF, de Souza CTV. Social stigmatization of cutaneous leishmaniasis in the state of Rio de Janeiro, Brazil. *Reciis—Rev Eletron Comun Inf Inov Saúde.* 2017; 11(3):1–12.
45. Semeneh G. The Psycho-Social Impact of Cutaneous Leishmaniasis on People Infected by the Disease. M.S.W. Thesis, Addis Ababa University. 2012. Available from: <https://pdfs.semanticscholar.org/a3e5/d948d622915955a199ab52ac30b06ba3489d.pdf>.
46. Chahed MK, Bellali H, Ben Jemaa S, Bellaj T. Psychological and Psychosocial Consequences of Zoonotic Cutaneous Leishmaniasis among Women in Tunisia: Preliminary Findings from an Exploratory Study. *PLoS Negl Trop Dis.* 2016; 10(10):e0005090. <https://doi.org/10.1371/journal.pntd.0005090> PMID: 27788184
47. Elsaie ML, Ibrahim SM. The effect of pulsed dye laser on cutaneous leishmaniasis and its impact on the dermatology life quality index. *J Cosmet Laser Ther.* 2017; 20(3):152–155.
48. Department of Dermatology—Quality of Life Questionnaires. DLQI Instructions for use and scoring. Cardiff University. Available from: <http://sites.cardiff.ac.uk/dermatology/quality-of-life/dermatology-quality-of-life-index-dlqi/dlqi-instructions-for-use-and-scoring/>.
49. Handjani F, Kalafi A. Impact of dermatological diseases on family members of the patients using Family Dermatology Life Quality Index: A preliminary study in Iran. *Iran J Dermatol.* 2013; 16(4):128–131.
50. Sampogna F, Abeni D. Interpretation of Skindex-29 Scores. *J Investig Derm.* 2011; 131(9):1790–1792.
51. Nilforoushzadeh MA, Roohafza H, Jaffary F, Khatuni M. Comparison of Quality of Life in Women Suffering from Cutaneous Leishmaniasis Treated with Topical and Systemic Glucantime along with Psychiatric Consultation Compared with the Group without Psychiatric Consultation. *J Skin Leishman.* 2010; 1(1):28–32.
52. Ranawaka RR, Weerakoon HS, de Silva SHP. The Quality of Life of Sri Lankan Patients with Cutaneous Leishmaniasis. *Mymensingh Med J.* 2014; 23(2):345–351. PMID: 24858165
53. Toledo ACC Jr, da Silver RE, Carmo RF, Amaral TA, Luz ZM, Rabello A. Assessment of the quality of life of patients with cutaneous leishmaniasis in Belo Horizonte, Brazil, 2009–2010. A pilot study. *Trans R Soc Trop Med Hyg.* 2013; 107(5):335–336. <https://doi.org/10.1093/trstmh/trt021> PMID: 23474473
54. Vares B, Mohseni M, Heshmatkhan A, Farjzadeh H, Shamsi-Meymandi S, Rehnama Z et al. Quality of Life in Patients with Cutaneous Leishmaniasis. *Arch Iran Med.* 2013; 16(8):474–477. PMID: 23906253
55. Bennis I, Thys S, Filali H, De Brouwere V, Sahibi H, Boelaert M. Psychosocial impact of scars due to cutaneous leishmaniasis on high school students in Errachidia province, Morocco. *Infect Dis Pov.* 2017; 6:46.
56. Kotrulja L, Tadinac M, Jokić-Begić N, Gregurek R. A Multivariate Analysis of Clinical Severity, Psychological Distress and Psychopathological Traits in Psoriatic Patients. *Acta Derm Venereol.* 2010; 90(3):251–256. <https://doi.org/10.2340/00015555-0838> PMID: 20526541
57. Abazid N, Jones C, Davies CR. Knowledge, attitudes and practices about leishmaniasis among cutaneous leishmaniasis patients in Aleppo, Syrian Arab Republic. *East Mediterr Health J.* 2012; 18(1):7–14. PMID: 22360005
58. Fernando SD, Siriwardana HV, Guneratne KA, Rajapaksa LC. Some sociological aspects of cutaneous leishmaniasis in patients attending a tertiary referral centre in Colombo, Sri Lanka. *Int Health.* 2010; 2(1):69–74. <https://doi.org/10.1016/j.inhe.2009.12.002> PMID: 24037054
59. Ramdas S, van der Geest S, Schallig HDFH. Nuancing stigma through ethnography: the case of cutaneous leishmaniasis in Suriname. *Soc Sci Med.* 2016; 151:139–146. <https://doi.org/10.1016/j.socscimed.2015.12.044> PMID: 26802370
60. Reithinger R, Aadil K, Kolaczinski J, Mohsen M, Hami S. Social Impact of Leishmaniasis, Afghanistan. *Emerg Infect Dis.* 2005; 11(4):634–636. <https://doi.org/10.3201/eid1104.040945> PMID: 15834984

61. Ruoti M, Oddone R, Lampert N, Orué E, Miles MA, Alexander N et al. Mucocutaneous leishmaniasis: knowledge, attitudes, and practices among Paraguayan communities, patients, and health professionals. *J Trop Med*. 2013; 2013:538629. <https://doi.org/10.1155/2013/538629> PMID: 23690792
62. Weigel MM, Armijos RX, Racines RJ, Zurita C, Izurieta R, Herrera E et al. Cutaneous Leishmaniasis in Subtropical Ecuador: Popular Perceptions, Knowledge, and Treatment. *Bull Pan Am Health Organ*. 1994; 28(2):142–155. PMID: 8069334
63. Alorfi A. Healthcare workers' perception and experience of impacts of Cutaneous Leishmaniasis in Al-Madinah Region of the kingdom of Saudi Arabia. M.Sc. Thesis, Liverpool School of Tropical Medicine. 2016.
64. da Silva MR, Lopes RLM. The american tegumentary leishmaniasis in the perspective of who lives it. *Online Braz J Nurs*. 2004; 3(2):16–24.
65. Guevara BG. The contribution of ethnography to knowledge on socio-cultural codes related to localized cutaneous leishmaniasis in a health education program in Venezuela. *Cad Saúde Pública Rio de Janeiro*. 2007; 23:S75–S83.
66. Martins ACdC. Percepção do risco de zoonoses em pacientes atendidos no Instituto Nacional de Infecologia Evandro Chagas. Universidade de Coimbra. 2014. Available from: <https://estudogeral.sib.uc.pt/handle/10316/32570>.
67. Reyburn H, Koggel M, Sharifi AS. Social and psychological consequences of cutaneous leishmaniasis in Kabul Afghanistan. *Healthnet International*. 2000. Available from: <http://www.afghandata.org:8080/xmlui/handle/azu/4484>.
68. Stewart CC, Brieger WR. Community views on cutaneous leishmaniasis in Istalif, Afghanistan: Implications for treatment and prevention. *Intl Quart Commun Health Educ*. 2009; 29(2):123–142.
69. Nandha B, Srinivasan R, Jambulingam P. Cutaneous Leishmaniasis: knowledge, attitude and practices of the inhabitants of the Kani forest tribal settlements of Tiruvananthapuram district, Kerala, India. *Health Educ Res*. 2014; 29(6):1049–1057. <https://doi.org/10.1093/her/cyu064> PMID: 25325998
70. WHO. Global Health Observatory data repository: Number of cases of cutaneous leishmaniasis reported. WHO. 2018. Available from: <http://apps.who.int/gho/data/node.main.NTDLEISHCNUM?lang=en>.
71. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J et al. Leishmaniasis Worldwide and Global Estimates of Its Incidence. *PLoS One*. 2012; 7(5):e35671. <https://doi.org/10.1371/journal.pone.0035671> PMID: 22693548
72. PAHO/WHO. Informe Epidemiológico de las Américas: Leishmaniasis. PAHO. 2015. Available from: <http://iris.paho.org/xmlui/handle/123456789/10069>.
73. PAHO/WHO. Epidemiological Report of the Americas: Leishmaniasis. PAHO. 2017. Available from: <http://iris.paho.org/xmlui/handle/123456789/34112>.
74. WHO. Leishmaniasis: Country profiles. WHO. Available from: http://www.who.int/leishmaniasis/burden/Country_profiles/en/.
75. Global Burden of Disease Collaborator Network. Global Burden of Disease Study 2016 (GBD 2016) Disability Weights. Institute of Health Metrics and Evaluation (IHME). 2017. Available from: <http://ghdx.healthdata.org/record/global-burden-disease-study-2016-gbd-2016-disability-weights>.
76. GBD 2016 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet*. 2017; 390(10100):1260–344. [https://doi.org/10.1016/S0140-6736\(17\)32130-X](https://doi.org/10.1016/S0140-6736(17)32130-X) PMID: 28919118
77. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 2016; 388(10053):1545–602. [https://doi.org/10.1016/S0140-6736\(16\)31678-6](https://doi.org/10.1016/S0140-6736(16)31678-6) PMID: 27733282
78. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet*. 2015; 386(9995):743–800. [https://doi.org/10.1016/S0140-6736\(15\)60692-4](https://doi.org/10.1016/S0140-6736(15)60692-4) PMID: 26063472
79. Hotez PJ, Alvarado M, Basáñez MG, Bolliger I, Bourne R, Boussinesq M et al. The Global Burden of Disease Study 2010: Interpretation and Implications for the Neglected Tropical Diseases. *PLoS Negl Trop Dis*. 2014; 8(7):e2865. <https://doi.org/10.1371/journal.pntd.0002865> PMID: 25058013
80. Costa JML, Vale KC, Cecílio IN, Osaki NK, Netto EM, Tada MS et al. Psicossociais e estigmatizantes da Leishmaniose cutâneo-mucosa. *Rev Soc Brasil Med Trop*. 1987; 20(2):77–82.

81. Bennis I, De Brouwere V, Belrhiti Z, Sahibi H, Boelaert M. Psychosocial burden of localised cutaneous Leishmaniasis: a scoping review. *BMC Public Health*. 2018; 18(1):358. <https://doi.org/10.1186/s12889-018-5260-9> PMID: 29544463

UNCORRECTED PROOF